Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 85 of 1,261
  1. US 12129263

    Kinase inhibitors and uses thereof

    DENALI THERAPEUTICS INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  2. US 12128133

    Ingestible device with expandable enclosure

    Rani Therapeutics, LLC · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  3. US 12129469

    Modified short interfering nucleic acid (siNA) molecules and uses thereof

    Aligos Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  4. US 12128034

    Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  5. US 12128013

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  6. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  7. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  8. US 12128014

    Use of thiol compounds to treat neurological disease

    MERCAPTOR DISCOVERIES, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  9. US 12129471

    Materials and methods for treatment of human genetic diseases including hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  10. US 12129476

    Methods for measuring the potency of AADC viral vectors

    VOYAGER THERAPEUTICS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  11. US 12128033

    Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

    Neurocrine Biosciences, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  12. US 12128052

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  13. US 12129222

    Production of bitter principle derivatives

    Julius-Maximilians-Universitaet · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  14. US 12128090

    Methods of prophylactic treatment using recombinant VWF (rVWF)

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  15. US 12128058

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  16. WO 2024219427

    PROCÉDÉ DE PRODUCTION DE LYMPHOCYTES INNÉS DE TYPE 2

    UNIV KYOTO [JP] · Granted Oct 24, 2024 · Expires Oct 19, 2044

    granted
  17. US 12121571

    Recombinant L-asparaginase

    Jazz Pharmaceuticals Ireland Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  18. US 12121522

    Methods of treating cancer with an mTOR inhibitor

    Revolution Medicines, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  19. US 12123015

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  20. US 12122998

    Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

    CRISPR THERAPEUTICS AG · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  21. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  22. US 12121569

    Methods and compositions for CNS delivery of iduronate-2-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  23. US 12121525

    Methods for treating GI syndrome and graft versus host disease

    The Board of Regents of the University of Texas System · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  24. US 12121288

    Combination tumor treatment

    Regents of the University of Minnesota · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.